Browsing by Subject "Cannabinoid"
Now showing items 1-6 of 6
-
Biased Agonists and Allosteric Modulators of the Type 1 Cannabinoid Receptor: Potential Treatments for Huntington Disease
(2016-04-05)Huntington disease (HD) is caused by the inheritance of a single copy of the mutant huntingtin gene. HD patients suffer from progressive cognitive decline, psychoses, depression, an inability to gain and maintain weight, ... -
CANNABINOID 2 RECEPTOR-BASED MODULATION OF THE IMMUNE RESPONSE IN EXPERIMENTAL MODELS OF CNS INJURY
(2019-06-20)One of the most important outcome-limiting medical risks after an acute CNS injury, such as stroke, spinal cord or traumatic brain injury, is an increased susceptibility to infections. This dysregulation of the immune ... -
CANNABINOIDS REGULATE TYPE 1 CANNABINOID RECEPTOR EXPRESSION IN CELL CULTURE MODELS OF HUNTINGTON'S DISEASE
(2012-08-10)Type 1 cannabinoid receptor (CB1) levels decline in the striatum of animal models of Huntington’s disease (HD) and in the brains of human patients suffering from HD prior to other pathogenic changes. CB1 levels can be ... -
Experimental Cannabinoid Receptor 2 Activation in Lipopolysaccharide-Induced Interstitial Cystitis in Mice
(2020-12-18)Interstitial cystitis (IC) is a chronic pain disorder of the urinary bladder that causes symptoms of persistent pelvic pain, nocturia, and dysuria with no curative treatment. Medical management is therefore directed toward ... -
Modulation of Acute Lung Injury-Associated Systemic Inflammation by the Cannabinoid Type 2 Receptor Agonist HU-308
(2024-07-09)Acute lung injury (ALI), clinically diagnosed as acute respiratory distress syndrome (ARDS), is a severe inflammatory syndrome characterized by pulmonary edema and refractory hypoxemia. Many patients with ARDS succumb to ... -
Strategies for Neuroprotection and Intraocular Pressure Modulation in Experimental Models of Glaucoma
(2020-01-21)Glaucoma is a blinding eye disease caused by death of retinal ganglion cells (RGCs). Intraocular pressure (IOP) is the only modifiable risk factor, and is the target of all current glaucoma therapeutics. However, IOP ...